| Falls Run Nursing And Rehab Center | |
| 140 Brimley Drive, Fredericksburg, Virginia 22406 | |
| (540) 752-0111 | |
| Name | Falls Run Nursing And Rehab Center |
|---|---|
| Location | 140 Brimley Drive, Fredericksburg, Virginia |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 90 |
| Occupancy Rate | 80.89% |
| Medicare ID (CCN) | 495407 |
| Legal Business Name | Stafford Healthcare Group, Inc. |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1295134476 |
| Address | 140 Brimley Dr, Fredericksburg, VA 22406 |
| Phone Number | 540-752-0111 |
News Archive
Nonalcoholic fatty liver disease, or NAFLD, which affects roughly 100 million Americans, costs the United States healthcare system $32 billion annually, according to a first-of-its-kind study by Intermountain Healthcare researchers on the economic impact of the disease.
HealthDay/Bloomberg BusinessWeek: With tens of millions of patients newly insured under the law, "[s]ome experts worry that there could be longer wait times to see a doctor, particularly in rural areas and underserved markets where primary-care physicians are in short supply. … [P]rimary-care physicians make up only 35 percent of America's physician workforce, and the pipeline of fresh talent is tapering off.
"The promise of health care reform is that it will provide all Americans coverage, allow them to keep their coverage if they like it, and bends the cost curve to put the system on a sustainable path. These are the standards by which any reform bill should be judged, and the Senate bill falls short of meeting them. We believe that these issues can be addressed and improved to achieve these goals, and we will continue to work with policymakers toward that end.
Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.
› Verified 1 days ago
| NPI Number | 1366115941 |
| Organization Name | STAFFORD II HEALTHCARE GROUP, LLC |
| Address | 55 Brimley Drive, Fredericksburg, VA 22406 |
| Phone Number | 540-701-9480 |
News Archive
Nonalcoholic fatty liver disease, or NAFLD, which affects roughly 100 million Americans, costs the United States healthcare system $32 billion annually, according to a first-of-its-kind study by Intermountain Healthcare researchers on the economic impact of the disease.
HealthDay/Bloomberg BusinessWeek: With tens of millions of patients newly insured under the law, "[s]ome experts worry that there could be longer wait times to see a doctor, particularly in rural areas and underserved markets where primary-care physicians are in short supply. … [P]rimary-care physicians make up only 35 percent of America's physician workforce, and the pipeline of fresh talent is tapering off.
"The promise of health care reform is that it will provide all Americans coverage, allow them to keep their coverage if they like it, and bends the cost curve to put the system on a sustainable path. These are the standards by which any reform bill should be judged, and the Senate bill falls short of meeting them. We believe that these issues can be addressed and improved to achieve these goals, and we will continue to work with policymakers toward that end.
Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.
› Verified 1 days ago
| NPI Number | 1891019733 |
| Organization Name | STAFFORD HEALTHCARE GROUP, INC. |
| Doing Business As | FALLS RUN NURSING AND REHABILITATION |
| Address | 140 Brimley Drive, Fredericksburg, VA 22406 |
| Phone Number | 540-752-0111 |
News Archive
Nonalcoholic fatty liver disease, or NAFLD, which affects roughly 100 million Americans, costs the United States healthcare system $32 billion annually, according to a first-of-its-kind study by Intermountain Healthcare researchers on the economic impact of the disease.
HealthDay/Bloomberg BusinessWeek: With tens of millions of patients newly insured under the law, "[s]ome experts worry that there could be longer wait times to see a doctor, particularly in rural areas and underserved markets where primary-care physicians are in short supply. … [P]rimary-care physicians make up only 35 percent of America's physician workforce, and the pipeline of fresh talent is tapering off.
"The promise of health care reform is that it will provide all Americans coverage, allow them to keep their coverage if they like it, and bends the cost curve to put the system on a sustainable path. These are the standards by which any reform bill should be judged, and the Senate bill falls short of meeting them. We believe that these issues can be addressed and improved to achieve these goals, and we will continue to work with policymakers toward that end.
Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.
› Verified 1 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Nonalcoholic fatty liver disease, or NAFLD, which affects roughly 100 million Americans, costs the United States healthcare system $32 billion annually, according to a first-of-its-kind study by Intermountain Healthcare researchers on the economic impact of the disease.
HealthDay/Bloomberg BusinessWeek: With tens of millions of patients newly insured under the law, "[s]ome experts worry that there could be longer wait times to see a doctor, particularly in rural areas and underserved markets where primary-care physicians are in short supply. … [P]rimary-care physicians make up only 35 percent of America's physician workforce, and the pipeline of fresh talent is tapering off.
"The promise of health care reform is that it will provide all Americans coverage, allow them to keep their coverage if they like it, and bends the cost curve to put the system on a sustainable path. These are the standards by which any reform bill should be judged, and the Senate bill falls short of meeting them. We believe that these issues can be addressed and improved to achieve these goals, and we will continue to work with policymakers toward that end.
Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.
› Verified 1 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 17.5 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 2.12 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 44.25 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.02 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.97 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0.93 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 12.32 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.79 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 20.28 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 12.98 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 3.03 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.02 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 69.65 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 88.65 | 82.93 |
News Archive
Nonalcoholic fatty liver disease, or NAFLD, which affects roughly 100 million Americans, costs the United States healthcare system $32 billion annually, according to a first-of-its-kind study by Intermountain Healthcare researchers on the economic impact of the disease.
HealthDay/Bloomberg BusinessWeek: With tens of millions of patients newly insured under the law, "[s]ome experts worry that there could be longer wait times to see a doctor, particularly in rural areas and underserved markets where primary-care physicians are in short supply. … [P]rimary-care physicians make up only 35 percent of America's physician workforce, and the pipeline of fresh talent is tapering off.
"The promise of health care reform is that it will provide all Americans coverage, allow them to keep their coverage if they like it, and bends the cost curve to put the system on a sustainable path. These are the standards by which any reform bill should be judged, and the Senate bill falls short of meeting them. We believe that these issues can be addressed and improved to achieve these goals, and we will continue to work with policymakers toward that end.
Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.
› Verified 1 days ago
Fredericksburg Health And Rehab Location: 3900 Plank Road, Fredericksburg, Virginia 22407 Phone: (540) 786-8351 | |
Carriage Hill Health And Rehab Center Location: 6106 Health Center Lane, Fredericksburg, Virginia 22407 Phone: (540) 785-1120 | |
Falls Run Nursing And Rehab Center Location: 140 Brimley Drive, Fredericksburg, Virginia 22406 Phone: (540) 752-0111 |